A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 362-367

  Rutherford, Thomas ^a   Orr, James ^b   Grendys, Edward ^b   Edwards, Robert ^c   Krivak, Thomas C ^c   Holloway, Robert ^d   Moore, Richard G ^e   Puls, Larry ^f   Tillmanns, Todd ^g   Schink, Julian C ^h   Brower, Stacey L ⁱ   Tian, Chunqiao ⁱ   Herzog, Thomas J ^j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Florida Society of Gynecologic Oncologists   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^e BROWN UNIVERSITY   (United States)

^f Cancer Centers of the Carolinas   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ PA ^*  (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

Chemoresponse assay; Ovarian cancer; Prospective clinical trial

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; FOLLOW UP; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ONCOLOGIST; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84886093926     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.009     Document Type: Article

References (33)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. T. Thigpen A rational approach to the management of recurrent or persistent ovarian carcinoma Clin Obstet Gynecol 55 2012 114 130
3. S.L. Cooke, and J.D. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol 12 2011 1169 1174
4. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
5. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 10 1992 513 514
6. M.G. Kris, N.J. Meropol, and E.P. Winer Accelerating progress against cancer: ASCO's blueprint for transforming clinical and translational cancer research http://www.asco.org/sites/default/files/blueprint.pdf 2011
7. R.W. Holloway, R.S. Mehta, N.J. Finkler, K.T. Li, C.E. McLaren, and R.J. Parker Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol 87 2002 8 16
8. A.C. Pant, T. Diaz-Montes, E. Tanner, S. Ahmad, R.L. Giuntoli, and R.W. Holloway Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer J Chemother 22 2010 270 274
9. K. Matsuo, M.L. Eno, D.D. Im, N.B. Rosenshein, and A.K. Sood Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma Gynecol Oncol 116 2010 61 65
10. H. Gallion, W.A. Christopherson, R.L. Coleman, L. Demars, T. Herzog, and S. Hosford Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay Int J Gynecol Cancer 16 2006 194 201
11. T.J. Herzog, T.C. Krivak, A. Nickles Fader, and R.L. Coleman Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer Am J Obstet Gynecol 203 68 2010 e1 e6
12. R.W. Holloway Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer Gynecol Oncol 116 2010 147 148
13. K. Matsuo, V.K. Bond, M.L. Eno, D.D. Im, and N.B. Rosenshein Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer Int J Cancer 125 2009 2721 2727
14. I.A. Cree Chemosensitivity and chemoresistance testing in ovarian cancer Curr Opin Obstet Gynecol 21 2009 39 43
15. J.C. Schink, and L.J. Copeland Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer J Natl Compr Canc Netw 9 2011 115 120
16. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
17. P.M. Bossuyt, J.B. Reitsma, D.E. Bruns, C.A. Gatsonis, P.P. Glasziou, and L.M. Irwig The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration Clin Chem 49 2003 7 18
18. S.L. Brower, J.E. Fensterer, and J.E. Bush The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy G. Mor, A.B. Alvero, Methods in molecular biology, apoptosis and cancer vol. 414 2008 Humana Press Inc. Totowa, NJ 57 78
19. J.H. Heinzman, S.D. Rice, and L.A. Corkan Robotic liquid handlers and semiautomated cell quantification systems increase consistency and reproducibility in high-throughput, cell-based assay JALA 15 2010 7 15
20. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627
21. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology Ovarian cancer: including fallopian tube cancer and primary peritoneal cancer. Version 1.2013 2013
22. I.A. Cree, C.M. Kurbacher, A. Lamont, A.C. Hindley, and S. Love A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer Anticancer Drugs 18 2007 1093 1101
23. R. Simon, and A. Maitournam Evaluating the efficiency of targeted designs for randomized clinical trials Clin Cancer Res 10 2004 6759 6763
24. D.J. Sargent, B.A. Conley, C. Allegra, and L. Collette Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027
25. B. Freidlin, L.M. McShane, and E.L. Korn Randomized clinical trials with biomarkers: design issues J Natl Cancer Inst 102 2010 152 160
26. P. Deverka, D. Messner, and T. Dutta Evaluation of clinical validity and clinical utility of actionable molecular diagnostic tests in adult oncology. Center for Medical Technology Policy http://www.cmtpnet.org/wp-content/uploads/ downloads/2013/07/CMTP-MDx-EGD07-17-2013.pdf 2013
27. R.L. Coleman, B.J. Monk, A.K. Sood, and T.J. Herzog Latest research and treatment of advanced-stage epithelial ovarian cancer Nat Rev Clin Oncol 10 2013 211 224
28. T.J. Herzog Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 10 2004 7439 7449
29. T.J. Perren, A.M. Swart, and J. Pfisterer A phase III trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
30. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
31. E. Pujade-Lauraine, F. Hilpert, and B. Weber AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 15 Suppl. 2012 [LBA5002]
32. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
33. V. Loizzi, J.K. Chan, K. Osann, F. Cappuccini, P.J. DiSaia, and M.L. Berman Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy Am J Obstet Gynecol 189 2003 1301 1307